Abstract:OBJECTIVE:To observe the correlation between long term efficacy/safety and treatment cycles of rh-endostatin (endostar) combined with TP (paclitaxel plus cisplatin/carboplatin) or NP (navelbine plus cisplatin/carboplatin) regimens in patients with advanced non-small cell lung cancer (NSCLC).METHODS:Twenty-five patients with advanced NSCLC confirmed by histopathology and/or cytology were enrolled in this study. Twenty-one patients underwent endostar combined with NP regimen and other four patients underwent endostar combined with TP regimen (all repeated 21 days) treatment. The therapeutic effects, quality of life (QOL) and adverse effects were evaluated according to RECIST criteria, Karnofsky performance scores and WHO grading of adverse effects, respectively. Our intention was to make knowledge of the therapeutic effects, median time to progression, one-year survival rate, median overall survival and adverse reactions. The amount of circulating endothelial cells (CEC) in peripheral blood was measured by flow cytometry.RESULTS:All the 25 patients were evaluable for efficacy and safety. They were comprised of 5 cases of PR, 14 cases of SD and 6 cases of PD. Of the 25 cases, RR was obtained in 5 cases (20.0%), CBR in 19 cases (76.0%), mTTP was 8 months and mOS was 19 months. Of the 14 patients with short treatment cycles (< 4), PR was obtained in 2 cases, SD in 6 cases and PD in 6 cases, RR was 14.3%. Of the 8 patients who obtained PR or SD, the median TTP was 6 months and median overall survival was 18 months. Of the 11 patients with long treatment cycles (≥ 4), PR was obtained in 3 cases, SD in 8 cases, RR was 27.3%, mTTP was 17 months and mOS was 26 months. After treatment, the amount of activated CECs was increased by (293 ± 12)/10(5) in patients with short treatment cycles, and decreased by (243 ± 181)/10(5) in patients with long treatment cycles. A positive correlation was found between the changes of activated CECs after therapy, time to progression (TTP) and treatment cycles (r = 0.970, P = 0.001; r = 0.829, P = 0.042, respectively). The quality of life (QOL) was improved in 12 cases (48.0%), stable in 10 cases (40.0%), and decreased in 3 cases (12.0%). Grade 3 and 4 toxicities were mainly related with chemotherapeutics, including neutropenia in 4 cases (16.0%), vomiting in 3 cases (12.0%) and arrhythmia in 1 case. No hypertension was observed. All the adverse reactions did not affect the following treatment, and there was no significant difference in incidence rate of grade 3 and 4 adverse events between the patients treated with long-term and short-term cycles.CONCLUSIONS:Endostar combined with TP or NP regimen chemotherapy is effective and safe in the treatment of advanced NSCLC, especially in patients with long term treatment cycles which can effectively prolong TTP and reach long term survival, but not increase adverse events. The QOL of patients can be improved or remain stable. The changes of CECs may be used as a useful maker in predicting the efficacy of the combination treatment.

Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

The Therapeuatic Effect of Endostar on Soft Carotid Plaque Neovascularization in Patients with Non-small Cell Lung Cancer

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

The Efficacy and Safety of Endostar Combined Gemcitabine and Cisplatin in the Treatment of Non-Small Cell Lung Cancer: a Meta-Analysis

Ced or metastatic lung squamous cell carcinoma

Platinum-based chemotherapy combined with endostar in the treatment of advanced NSCLC: A real world study.

Efficacy and Safety of Endostar in the Treatment of Advanced Lung Squamous Cell Carcinoma.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

Influence of Different Drug Delivery Methods for Endostar Combined with a Gemcitabine/cisplatin Regimen in Locally Advanced or Metastatic Lung Squamous Cell Carcinoma

Long‐term Results of a Randomized, Double‐blind, and Placebo‐controlled Phase III Trial: Endostar (rh‐endostatin) Versus Placebo in Combination with Vinorelbine and Cisplatin in Advanced Non‐small Cell Lung Cancer

[Efficacy of Endostar Combined with Chemotherapy in Multi-Cycle Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Endostar in Combination with Postoperative Adjuvant Chemotherapy Prolongs the Disease Free Survival of Stage IIIA NSCLC Patients with High VEGF Expression

Enhanced Anti-Tumor and Anti-Angiogenic Effects of Metronomic Cyclophosphamide Combined with Endostar in a Xenograft Model of Human Lung Cancer

Endostar, A Recombined Humanized Endostatin, Enhances The Radioresponse For Human Nasopharyngeal Carcinoma And Human Lung Adenocarcinoma Xenografts In Mice

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

A Randomized Clinical Trail of Endostar Combined with Concurrent Chemoradiotherapy in Treatment of Local Advanced Non-Small Cell Lung Cancer

A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC

Efficacy and Outcome Analysis: Combination of Endostar and Chemotherapy As a Neoadjuvant Treatment of Stage IIIA/IIIB Squamous Cell Lung Cancer

Randomized Phase Ii Study of Recombinant Human Endostatin in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer (Nct00912392).